West Pharmaceutical Services, I (WST) Q3 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure · Editorial policy
Key numbers
- Adjusted EPS
- $2.66
- Estimate
- $2.20
- Surprise
- +21.1%
- Revenue (period 2026-09-30)
- $874.5M
- Score at report (before → after)
- 6.2 → 6.2/10
Revenue source: xbrl.
How the report landed
West Pharmaceutical Services, I (WST) beat the $2.20 estimate with adjusted EPS of $2.66 — a large 21.1% upside surprise. TrendMatrix's engine moved from Buy (Wait) (6.2/10) to Hold at 6.2/10 after the report.
Where TrendMatrix's rating stands now
TrendMatrix currently rates WST Buy (Wait) at 6.1/10.
4 of the last 4 quarters beat the estimate; this quarter's +21.1% surprise compares with a +18.4% four-quarter average. Next scheduled report: 2027-02-18.
What supports the rating
- V7 quality resilience bonus: +0.2 (Q=7.6 in RISK_OFF)
- Sector modifier (Healthcare): +0.5
What argues against it
- Concentration risk — Supplier: single-source raw materials
- Concentration risk — Geographic: international sales (56.7%)
- Thin upside margin: 6.9%
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $396.69
- Entry target
- $392.13
- Price target
- $423.90
- Stop
- $375.04
- Upside to target
- +6.9%
- Reward-to-risk
- 1.2:1
At 45.3× trailing and 38.9× forward earnings, consensus estimates imply little change in earnings power.
Model outputs from TrendMatrix’s engine as of 2026-11-19 — shown for context, not personalized investment advice.
WST at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $28.14B
- P/E (fwd)
- 38.9
- P/E (ttm)
- 45.3
- 52-week range
- $223.83–$438.27
- Off 52-week high
- 9.5%
- RSI (14)
- 39
- Volume vs avg
- 1.05×
- Score today
- 6.1/10